Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Feasibility trial success could mean a new therapy, but not for a few years yet.
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?